Oruka Therapeutics, Inc.(ORKA)Earnings, Financials & Key Ratios
ORKA•NASDAQ
$69.79
$3.38B mkt cap·Price updated May 6, 2026
AboutOruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Show more
- Revenue$0
- EBITDA-$88M-805.7%
- Net Income-$84M-743.5%
- EPS (Diluted)-4.99+39.7%
- ROE-39.5%-84.5%
- ROIC-41.15%
- Debt/Equity0.00-72.4%
- Interest Coverage-60.03
ORKA Key Insights
Oruka Therapeutics, Inc. (ORKA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 16.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ORKA Price & Volume
Oruka Therapeutics, Inc. (ORKA) stock price & volume — 10-year historical chart
Loading chart...
ORKA Growth Metrics
Oruka Therapeutics, Inc. (ORKA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-94.56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM46.35%
Return on Capital
10 Years-59.98%
5 Years-44.58%
3 Years-33.96%
Last Year-41.48%
ORKA Recent Earnings
Oruka Therapeutics, Inc. (ORKA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (71%)
Q2 2026Latest
Mar 12, 2026EPS
$0.45
Est $0.61
+26.2%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.55
Est $0.56
+1.8%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$0.46
Est $0.48
+4.2%
Revenue
—
Q2 2025
May 14, 2025EPS
$0.40
Est $0.57
+29.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.45vs $0.61+26.2% | — |
| Q4 2025 | Nov 12, 2025 | $0.55vs $0.56+1.8% | — |
| Q3 2025 | Aug 11, 2025 | $0.46vs $0.48+4.2% | — |
| Q2 2025 | May 14, 2025 | $0.40vs $0.57+29.8% | — |
Based on last 12 quarters of dataView full earnings history →
ORKA Peer Comparison
Oruka Therapeutics, Inc. (ORKA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 SANA | 954.64M | 3.64 | -3.14 | -120.02% | 0.38 | |||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RAPT | 295.54M | 58.01 | -2.28 | -61.81% | 0.02 | |||
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare ORKA vs Peers
Oruka Therapeutics, Inc. (ORKA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ORKA Income Statement
Oruka Therapeutics, Inc. (ORKA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 19K | 24K | 27K | 22K | 89K | 93K | 91K | 114K | 27K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -19K▲ 0% | -24K▼ 26.3% | -27K▼ 12.5% | -22K▲ 18.5% | -89K▼ 304.5% | -93K▼ 4.5% | -91K▲ 2.2% | -114K▼ 25.3% | -27K▲ 76.3% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -58.33% | -26.32% | -12.5% | 18.52% | -304.55% | -4.49% | 2.15% | -25.27% | 76.32% | - |
| Operating Expenses | 11.44M | 16.59M | 18.68M | 8.1M | 5.72M | 9.67M | 19.24M | 9.73M | 88.1M | 125.95M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.37M | 4.24M | 4.61M | 3.86M | 3.89M | 4.68M | 5.41M | 5.26M | 13.04M | 20.62M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 7.06M | 12.35M | 14.08M | 4.24M | 1.83M | 4.99M | 13.83M | 4.46M | 75.06M | 105.33M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11.46M▲ 0% | -16.61M▼ 45.0% | -18.71M▼ 12.6% | -8.12M▲ 56.6% | -5.81M▲ 28.4% | -9.77M▼ 68.0% | -19.34M▼ 98.0% | -9.84M▲ 49.1% | -88.12M▼ 795.5% | -125.95M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -18.18% | -45.03% | -12.63% | 56.62% | 28.38% | -67.97% | -97.98% | 49.1% | -795.47% | - |
| EBITDA | -11.44M | -16.59M | -18.68M | -8.1M | -5.72M | -9.67M | -19.24M | -9.73M | -88.1M | -125.88M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -18.13% | -45.06% | -12.63% | 56.67% | 29.29% | -68.96% | -98.95% | 49.45% | -805.69% | -124.48% |
| D&A (Non-Cash Add-back) | 19K | 24K | 27K | 22K | 89K | 93K | 91K | 114K | 27K | 73.45K |
| EBIT | -11.45M | -16.44M | -18.55M | -7.96M | -5.64M | -9.74M | -19.32M | -9.93M | -82.26M | -113.31M |
| Net Interest Income | 14K | 169K | 0 | 0 | -7K | -9K | 0 | 675K | 4.39M | 16.31M |
| Interest Income | 14K | 169K | 0 | 0 | 0 | 0 | 0 | 675K | 5.86M | 16.31M |
| Interest Expense | 0 | 0 | 0 | 0 | 7K | 9K | 0 | 0 | 1.47M | 0 |
| Other Income/Expense | 10K | 169K | 161K | 154K | 165K | 19K | 13K | -85K | 4.4M | 16.71M |
| Pretax Income | -11.45M▲ 0% | -16.44M▼ 43.7% | -18.55M▼ 12.8% | -7.96M▲ 57.1% | -5.65M▲ 29.1% | -9.75M▼ 72.5% | -19.32M▼ 98.2% | -9.93M▲ 48.6% | -83.72M▼ 743.5% | -109.24M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | -61K | -31K | -167K | -9K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0.33% | 0.39% | 2.96% | 0.09% | 0% | 0% | 0% | 0% |
| Net Income | -11.45M▲ 0% | -16.44M▼ 43.7% | -18.49M▼ 12.4% | -7.93M▲ 57.1% | -5.48M▲ 30.9% | -9.74M▼ 77.6% | -19.32M▼ 98.4% | -9.93M▲ 48.6% | -83.72M▼ 743.5% | -109.24M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -18.12% | -43.68% | -12.44% | 57.1% | 30.9% | -77.64% | -98.42% | 48.63% | -743.48% | -94.56% |
| Net Income (Continuing) | -11.45M | -16.44M | -18.49M | -7.93M | -5.48M | -9.74M | -19.32M | -9.93M | -83.72M | -109.24M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -393.12▲ 0% | -390.96▲ 0.5% | -382.87▲ 2.1% | -123.73▲ 67.7% | -49.79▲ 59.8% | -8.40▲ 83.1% | -16.68▼ 98.6% | -8.27▲ 50.4% | -4.99▲ 39.7% | -2.48▲ 0% |
| EPS Growth % | 44.68% | 0.55% | 2.07% | 67.68% | 59.76% | 83.13% | -98.57% | 50.42% | 39.66% | 46.35% |
| EPS (Basic) | -393.12 | -390.96 | -382.87 | -123.73 | -49.79 | -8.40 | -16.68 | -8.27 | -4.99 | - |
| Diluted Shares Outstanding | 29.12K | 41.98K | 48.29K | 64.11K | 110.1K | 4.71M | 13.9M | 14.41M | 16.79M | 44.07M |
| Basic Shares Outstanding | 29.12K | 41.98K | 48.29K | 64.11K | 110.1K | 4.71M | 13.9M | 14.41M | 16.79M | 44.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ORKA Balance Sheet
Oruka Therapeutics, Inc. (ORKA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 38.92M | 21.45M | 12.3M | 6.78M | 8.48M | 49.97M | 54.42M | 42.7M | 376.87M | 355.16M |
| Cash & Short-Term Investments | 38.8M | 21.16M | 11.75M | 6.61M | 8.36M | 49.07M | 53.36M | 42.45M | 375.65M | 349.15M |
| Cash Only | 38.8M | 7.4M | 8.7M | 6.61M | 8.36M | 49.07M | 53.36M | 42.45M | 61.58M | 91.25M |
| Short-Term Investments | 0 | 13.76M | 3.05M | 0 | 0 | 0 | 0 | 0 | 314.07M | 257.9M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 114K | 282K | 547K | 169K | 117K | 897K | 1.06M | 254K | 1.22M | 6.01M |
| Total Non-Current Assets | 658K | 3.18M | 66K | 48K | 56K | 461K | 503K | 386K | 19.15M | 154.09M |
| Property, Plant & Equipment | 28K | 66K | 42K | 24K | 32K | 449K | 485K | 368K | 1.04M | 2.22M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 2.35M | 0 | 0 | 0 | 0 | 0 | 0 | 18.07M | 216.84M |
| Other Non-Current Assets | 630K | 766K | 24K | 24K | 24K | 12K | 18K | 18K | 43K | 352K |
| Total Assets | 39.57M▲ 0% | 24.63M▼ 37.8% | 12.37M▼ 49.8% | 6.83M▼ 44.8% | 8.54M▲ 25.1% | 50.43M▲ 490.8% | 54.92M▲ 8.9% | 43.09M▼ 21.6% | 396.02M▲ 819.2% | 509.25M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | 145.31% | -37.76% | -49.8% | -44.8% | 25.07% | 490.78% | 8.91% | -21.56% | 819.16% | 1906.44% |
| Total Current Liabilities | 1.5M | 2.4M | 2.07M | 793K | 926K | 3.5M | 3.5M | 1.13M | 13.04M | 20.97M |
| Accounts Payable | 0 | 0 | 622K | 230K | 418K | 1.77M | 1.12M | 334K | 3.46M | 2.21M |
| Days Payables Outstanding | - | - | 8.41K | 3.82K | 1.71K | 6.96K | 4.48K | 1.07K | 46.8K | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 25K | 41K | 100K | 103K | 213K | 419K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 835K | 1.68M | 691K | 413K | 354K | 870K | 1.36M | 522K | 7.33M | 15.49M |
| Current Ratio | 25.88x | 8.95x | 5.94x | 8.55x | 9.16x | 14.28x | 15.56x | 37.72x | 28.89x | 28.89x |
| Quick Ratio | 25.88x | 8.95x | 5.94x | 8.55x | 9.16x | 14.28x | 15.56x | 37.72x | 28.89x | 28.89x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 39K | 20K | 0 | 0 | 409K | 383K | 280K | 755K | 1.49M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 409K | 383K | 280K | 755K | 4.58M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 39K | 20K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.5M | 2.44M | 2.09M | 793K | 926K | 3.91M | 3.88M | 1.41M | 13.8M | 22.46M |
| Total Debt | 0 | 0 | 0 | 0 | 25K | 450K | 483K | 383K | 968K | 1.91M |
| Net Debt | -38.8M | -7.4M | -8.7M | -6.61M | -8.34M | -48.62M | -52.88M | -42.06M | -60.61M | -89.34M |
| Debt / Equity | - | - | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.71x |
| Interest Coverage | - | - | - | - | -830.57x | -1085.11x | - | - | -60.03x | - |
| Total Equity | 38.07M▲ 0% | 22.19M▼ 41.7% | 10.28M▼ 53.7% | 6.03M▼ 41.3% | 7.61M▲ 26.2% | 46.52M▲ 511.3% | 51.04M▲ 9.7% | 41.67M▼ 18.4% | 382.22M▲ 817.2% | 486.79M▲ 0% |
| Equity Growth % | 158.26% | -41.7% | -53.7% | -41.29% | 26.16% | 511.31% | 9.72% | -18.36% | 817.19% | 1935.54% |
| Book Value per Share | 1307.48 | 528.71 | 212.76 | 94.08 | 69.12 | 9.88 | 3.67 | 2.89 | 22.77 | 11.05 |
| Total Shareholders' Equity | 38.07M | 22.19M | 10.28M | 6.03M | 7.61M | 46.52M | 51.04M | 41.67M | 382.22M | 486.79M |
| Common Stock | 9K | 9K | 12K | 14K | 2K | 10K | 14K | 14K | 37K | 48K |
| Retained Earnings | -96.07M | -112.51M | -131M | -138.93M | -144.42M | -154.15M | -173.48M | -183.4M | -83.72M | -159.57M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -19K | -2K | 0 | 0 | 0 | 0 | 0 | -41K | 185K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ORKA Cash Flow Statement
Oruka Therapeutics, Inc. (ORKA) cash flow — operating, investing & free cash flow history
| Line item | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.53M | -14.99M | -17.47M | -8.24M | -4.8M | -7.72M | -18.76M | -10.91M | -57.84M | -57.84M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -11.99% | -42.27% | -16.58% | 52.82% | 41.76% | -60.9% | -142.87% | 41.84% | -430.03% | -13062.7% |
| Net Income | -11.45M | -16.44M | -18.49M | -7.93M | -5.48M | -9.74M | -19.32M | -9.93M | -83.72M | -109.24M |
| Depreciation & Amortization | 19K | 24K | 27K | 22K | 89K | 93K | 91K | 114K | 27K | 71K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.96M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 788K | 1.03M | 906K | 275K | 151K | 43K | 497K | 561K | 14.27M | 6.54M |
| Working Capital Changes | 104K | 400K | 85K | -608K | 441K | 1.88M | -28K | -1.66M | 11.59M | 622K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | -583K | -392K | 188K | 1.1M | -411K | -783K | 3.46M | 2.35M |
| Cash from Investing | -11K | -16.41M | 12.93M | 3.05M | -4K | -19K | -43K | -2K | -330.13M | -404.68M |
| Capital Expenditures | -11K | -12K | -3K | -4K | -4K | -19K | -43K | -2K | -189K | -164K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -452.29M |
| Cash from Financing | 33.99M | 0 | 5.85M | 3.1M | 6.56M | 48.45M | 23.09M | 0 | 449.54M | 169.49M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | -349K | -408K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1.11M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -193K | 0 | -256K | -311K | 0 | 0 | 0 | 0 | 0 | 139.99M |
| Net Change in Cash | 23.45M▲ 0% | -31.4M▼ 233.9% | 1.3M▲ 104.1% | -2.09M▼ 261.0% | 1.75M▲ 183.8% | 40.71M▲ 2219.5% | 4.29M▼ 89.5% | -10.91M▼ 354.5% | 24.14M▲ 321.2% | -319.62M▲ 0% |
| Free Cash Flow | -10.54M▲ 0% | -15M▼ 42.2% | -17.48M▼ 16.5% | -8.25M▲ 52.8% | -4.8M▲ 41.7% | -7.74M▼ 61.2% | -18.8M▼ 142.8% | -10.91M▲ 42.0% | -58.03M▼ 431.7% | -84.6M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -11.88% | -42.24% | -16.51% | 52.8% | 41.74% | -61.17% | -142.83% | 41.96% | -431.67% | -100.8% |
| FCF per Share | -362.16 | -357.31 | -361.85 | -128.64 | -43.64 | -1.64 | -1.35 | -0.76 | -3.46 | -3.46 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.91x | 0.94x | 1.04x | 0.88x | 0.79x | 0.97x | 1.10x | 0.69x | 0.77x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ORKA Key Ratios
Oruka Therapeutics, Inc. (ORKA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -43.34% | -54.57% | -113.89% | -97.3% | -80.37% | -35.98% | -39.61% | -21.41% | -39.5% | -27.7% |
| Return on Invested Capital (ROIC) | - | -177.22% | -171.5% | -1221.36% | - | - | - | - | -41.15% | -41.15% |
| Debt / Equity | - | - | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
| Interest Coverage | - | - | - | - | -830.57x | -1085.11x | - | - | -60.03x | - |
| FCF Conversion | 0.92x | 0.91x | 0.94x | 1.04x | 0.88x | 0.79x | 0.97x | 1.10x | 0.69x | 0.77x |
ORKA Frequently Asked Questions
Oruka Therapeutics, Inc. (ORKA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Oruka Therapeutics, Inc. (ORKA) grew revenue by 0.0% over the past year. Growth has been modest.
Oruka Therapeutics, Inc. (ORKA) reported a net loss of $109.2M for fiscal year 2024.
Dividend & Returns
Oruka Therapeutics, Inc. (ORKA) has a return on equity (ROE) of -39.5%. Negative ROE indicates the company is unprofitable.
Oruka Therapeutics, Inc. (ORKA) had negative free cash flow of $84.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More ORKA
Oruka Therapeutics, Inc. (ORKA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates